PYC Therapeutics presents RP11 clinical trial data at ARVO conference

PYC Therapeutics Limited (ASX: $PYC) announces the presentation of RP11 clinical trial data at the Association for Research in Vision and Ophthalmology (ARVO) conference in Seattle on Sunday 5 May 2024. The presentation will cover safety and efficacy data of the investigational drug candidate VP-001, with a focus on its potential in treating Retinitis Pigmentosa type 11 (RP11).

Executive Commentary on VP-001 for RP11

PYC Therapeutics is conducting clinical trials for VP-001, the first investigational drug candidate with disease-modifying potential in RP11. The safety and tolerability data from the ongoing clinical trials have shown no treatment emergent serious adverse events across all three patient cohorts dosed to date. Additionally, initial encouraging microperimetry data has demonstrated improvement in retinal sensitivity for one patient in cohort 3, who received 30 micrograms of VP-001. We are also refining the inclusion criteria for the next cohort of patients to focus on those at an earlier stage of disease progression. These developments are significant steps forward in our efforts to address the unmet medical needs of RP11 patients.

Summary of RP11 Clinical Trial Data Presentation

PYC Therapeutics, through the presentation by Associate Professor Fred Chen, has showcased the safety and efficacy data of VP-001 at the ARVO conference. The data indicates that VP-001 has demonstrated safety across all dose cohorts tested to date, with no serious adverse events observed. Furthermore, initial encouraging microperimetry data has shown improvement in retinal sensitivity for a patient in cohort 3, who received 30 micrograms of VP-001. The company is also planning to refine the inclusion criteria for the next cohort of patients to focus on those at an earlier stage of disease progression. These developments mark significant progress in the clinical trials for VP-001 and hold promise for addressing the unmet medical needs of RP11 patients.